Clinical trial NCT03634319: Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union
Official title: Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Glaucoma, Open-Angle
Lead sponsor: MicroOptx
Sponsor class: INDUSTRY
First posted: 2018-08-16
Enrollment: 10
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.

Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
Primary purpose: TREATMENT

Brief summary: This is prospective, non-randomized, single-arm study to assess the safety and effectiveness of lowering intraocular pressure with the Beacon Aqueous Microshunt. A total of 65 subjects will be enrolled at five centers. The primary endpoint will be assessed at 12 month follow-up.


Eligibility criteria: Inclusion Criteria:

1. Age 22 years and older.
2. Diagnosed with mild, moderate or severe open-angle glaucoma (OAG).
3. Best corrected vision acuity 20/25 or worse in the study eye.
4. Inadequate medical control of IOP, or target IOP not reached with intraocular pressure in the study eye greater than or equal to 20 mmHg.
5. At least two contiguous clock hours of intact conjunctiva near the limbus between clock hours of 09:00 and 03:00 in the study eye.
6. Adequate space in the anterior chamber of the study eye sufficient to support implant with the BAM, defined as two contiguous clock hours of scleral spur visualization via gonioscopy, without compression, in the superior 180 degrees of the anterior angle.
7. Any IOP-lowering medications should be stabilized at least 30 days prior to baseline measurements.
8. Able and willing to comply with protocol requirements.
9. Able to understand and sign the Informed Consent form.

Exclusion Criteria:

1. Active Neovascular Glaucoma in the study eye.
2. Pigmentary Glaucoma in the study eye.
3. Pseudoexfoliative Glaucoma in the study eye.
4. Any eye disease associated with the formation of free-floating material or tissue in the anterior chamber of the eye.
5. Corneal conditions in the study eye that may inhibit normal incisional healing (e.g. Fuch's dystrophy) or impair visualization of the implant inside the anterior chamber.
6. Anticipated need for ocular surgery within one year in the study eye.
7. Contact lens use in the study eye.
8. Clinically significant inflammation or infection in the study eye within 60 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) or any systemic infection. For purposes of this study, clinically significant is considered any such condition requiring prescription therapy.
9. Other clinical conditions:

   1. Poorly controlled diabetes (Type I or Type II) as determined by HbA1c \>8.
   2. Cancer requiring treatment during the duration of the study.
   3. Any drugs (e.g.: immunosuppressive drugs) or co- morbidity that might inhibit wound healing.
10. Participation in any other clinical trial during participation in this trial.
11. Life expectancy \<1 year.
12. Clinically significant macular degeneration in the study eye.
13. Patients who have undergone surgery in the trial eye within the last 6 months.
14. Planned combined cataract surgery.

If both eyes of a prospective trial participant are eligible, the eye with the highest intraocular pressure will be selected for implant.

Primary outcomes:
measure: Reduction in IOP
timeFrame: 12 Months
measure: Adverse Event Rate
timeFrame: 12 Months
Secondary outcomes:
measure: Mean Change from Baseline in IOP
timeFrame: 12 Months
measure: Responder Rate for 20% reduction
timeFrame: 12 Months
measure: Reduction in IOP lowering medication
timeFrame: 12 Months
Other outcomes:
Locations:
city: Bochum
country: Germany
facility: University Eye Hospital
city: Lübeck
country: Germany
facility: Universitatsklinikum Schleswig-Holstein
Study officials:
References: